GEMMA Biotherapeutics (GEMMABio) - a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson - announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.

The $34 million seed round was co-led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, with additional backing from Savanne Life Sciences. This funding will fuel GEMMABio's operational expansion and innovative gene therapy programs.

GEMMABio is a therapeutics company focused on advancing research and global access to life-changing advanced therapies for those living with rare diseases. The company will provide research and product development functions to bring gene therapy discoveries from the bench to the bedside faster and affordably.